David P. Holveck was appointed President, Chief Executive Officer, and a Director of Endo Pharmaceuticals in April 2008 and retired as of March 2013. Mr. Holveck brought over 40 years of pharmaceutical industry expertise to Endo, and was responsible for driving the strategic growth for the corporation and identifying opportunities for domestic and international expansion. Endo grew from a $1.3 billion business in 2008, to a diversified $3.0 billion healthcare solutions company in 2012.
Prior to joining Endo, Mr. Holveck was President of Johnson & Johnson Development Corporation (JJDC) and Vice President, Corporate Development of Johnson & Johnson since 2004. While at JJDC, Holveck was accountable for equity investments made on behalf of the enterprise and tasked with increasing strategic effectiveness of the company’s key investments. During his tenure, Holveck’s work helped chart a global approach to long term growth initiatives, and build a management and investment team with competencies aligned with the new JJDC vision. Mr. Holveck joined Johnson & Johnson as a company Group Chairman in 1999 following the acquisition of Centocor, Inc., by Johnson & Johnson. Holveck was Chief Executive Officer of Centocor, Inc. at the time of the acquisition and was instrumental in the smooth transition of Centocor into the Johnson and Johnson corporate culture.
Mr. Holveck joined Centocor in 1983 and progressed through various executive positions. In 1992, he assumed the role of President and Chief Operating Officer and later that year was named President and Chief Executive Officer. While in this role, Holveck solidified confidence of key shareholders in the organization, restructured the company’s financial underpinnings to increase profitability, and established partnering relationships with leading pharmaceutical companies for the development of various medicines.
Prior to joining Centocor, Mr. Holveck held positions with General Electric Company, Corning Glass Works, and Abbott Laboratories. While serving in these early management roles, Holveck built a foundation for his expertise in fundamental sales and marketing strategy. Mr. Holveck launched his career in the pharmaceutical industry after ending his service with the U.S. Navy after an honorable discharge. Prior to his military service, Holveck received his B.A. in Education from West Chester University.
In addition to his professional duties, Mr. Holveck has served in numerous leadership roles for several pharmaceutical industry professional organizations over the course of his career. Holveck currently serves on the Boards of the Kimmel Center, Children’s Hospital of Philadelphia, and West Chester University Foundation Board of Trustees, as well as the University City Science Center Emeritus Board. He previously served on the Boards of the Pharmaceutical Research & Manufacturers of America (PhRMA), the Biotechnology Industry Organization and the Biotechnology Institute. Mr. Holveck has received numerous accolades for his leadership in the pharmaceutical industry and beyond, including the Hubert J. P. Schoemaker Leadership Award to recognize leaders in the bioscience community, and the Crohn’s & Colitis Foundation of America Man of the Year.